WO1997001337A1 - The combination of topical nasal antihistamines and topical nasal steroids - Google Patents
The combination of topical nasal antihistamines and topical nasal steroids Download PDFInfo
- Publication number
- WO1997001337A1 WO1997001337A1 PCT/US1996/010789 US9610789W WO9701337A1 WO 1997001337 A1 WO1997001337 A1 WO 1997001337A1 US 9610789 W US9610789 W US 9610789W WO 9701337 A1 WO9701337 A1 WO 9701337A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nasal
- topical
- triamcinolone
- flunisolide
- constitutes
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
Definitions
- the present invention relates to prevention and treatment of the symptoms of seasonal and perennial allergic rhinitis. More particularly, the present invention relates to the prevention and treatment of the symptoms of seasonal and perennial allergic rhinitis by the application of a combination of topical nasal antihistamines and topical nasal steroids.
- rhinitis is most frequently caused by pollen, pollen fragments and mold spores.
- the airborne pollens, pollen fragments and mold spores are deposited on the nasal mucosa.
- rhinitis symptoms develop which include puffy, sore eyes, sneezing, nasal congestion, sinus headaches and fatigue.
- perennial allergic rhinitis The chronic symptoms of perennial allergic rhinitis are most frequently caused by reaction to perennial allergens, such as, house dust mite, mold, cockroach, animal saliva, urine, and dander.
- perennial allergens such as, house dust mite, mold, cockroach, animal saliva, urine, and dander.
- the symptoms resemble those of seasonal allergic rhinitis but the duration is year round or episodic depending upon the source of the allergens.
- Antihistamines are the primary medicaments employed to treat allergic rhinitis. Antihistamines are helpful to control sneezing, itching, and rhinorrhea as well as associated ocular symptoms but are ineffective in relieving nasal blockage. Antihistamines compete with histamine for binding to Hi receptors and thereby prevent the action of histamine which includes bronchospasm, edema, increased mucus secretion and itching.
- the antihistamines primarily in use today are orally active and administered.
- intranasally (topically) administered antihistamines including azelastine and levocabastine have also been shown to be useful antihistamines in the treatment of allergic rhinitis.
- the intranasally administered antihistamines have a quick onset of action because they are delivered directly to the site of activity.
- nasal steroids particularly the corticosteroids.
- Such steroids have powerful effects on immunologic and hormonal processes and are very effective in treating the inflammation which accompanies the allergic reaction.
- Suitable nasal steroids known in use today include beclamethasone, flunisolide, triamcinolone, dexamethasone and budesonide.
- a nasal spray or nasal drops for the treatment of allergic rhinitis comprising:
- topical nasal antihistamine to relieve histamine mediated symptoms
- topical nasal antihistamine is selected from the group consisting of levocabastine, azelastine and azatadine
- nasal steroid selected from the group consisting of beclomethasone, flunisolide, triamcinolone, dexamethasone and budesonide; and
- the topical antihistamines herein are potent H 1 receptor antagonists which relieve the histamine mediated symptoms, i.e. sneezing, runny nose, itchy nose, etc.
- the H 1 receptor antagonists block the receptor sites and thereby block the expression of the histamine effect.
- levocabastine from about 0.05 to about 10 mg and preferably from about 0.5 to about 5 mg should be administered in this combination every 4 to 12 hours.
- azelastine from about 0.05 to about 10 mg and preferably from about 0.5 to about 5 mg should be administered in this combination every 4 to 12 hours.
- azatadine from about 0.05 to about 10 and preferably from about 0.5 to about 5 mg should be administered in this combination every 4 to 12 hours.
- levocabastine should constitute of the nasal spray or nasal drops composition from about 0.2 to about 40 mg/ml and preferably from about 2 to about 20 mg/ml.
- azelastine should constitute of the nasal spray or nasal drops composition from about 0.2 to about 40 mg/ml and preferably from about 2 to about 20 mg/ml.
- azatadine should constitute from about 0.2 to about 40 mg/ml and preferably from about 2 to about 20 mg/ml.
- Levocabastine as used herein included e s levocabastine and its pharmaceutically acceptable acid addition salts. Suitable salts include the hydrochloric, hydrobromic, sulfuric, nitric, acetic, propionic, butanedioic, etc. salts. The preferred salt is hydrochloric.
- Levocabastine, (-)-[3S-1 (cis),3,4]-1- [4-cyano-4-(4-fluorophenyl)cyclohexyl]-3-methyl-4-phenyl-4-piperidine carboxylic acid is a well known compound and may be prepared by the method of U.S. Pat. 4,369,184, EP 34,415 or Stokbroekx, R. A., et al., Drug Dev. Res. 8: 87-93 (1986).
- Azelastine as used herein includes azelastine and its pharmacutically acceptable salts.
- Preferred are the acid addition salts, such as, the hydrohalo salts and salts with organic acids.
- Preferred salts include hydrochloridic hydrobromidic, embonic acid, maleic acid, citric acid and tartaric acid salts.
- Azelastine, 4-(p-chlorobenzyl)-2-[N-methyl-perhydroazepin-4-yl)-1-(2H)- phthalazinone, is a well known compound and may be prepared according to Belg. Pat. 778,269; Vogelsang et al., U.S. Pat. 3,813,384 and Scheffler et al., Arch. Pharm. 321 , 205 (1988).
- Azatadine as used herein includes azatadine and its pharmaceutically acceptable salts.
- Preferred salts of azatadine include its maleate, sulfate, succinate and acetate salts.
- Aztadine, 4-aza-5-(N-methyl-4-piperidinylidene)- 10,11-dinydro-5H-dibenzo[a,d]cycloheptene is a well known compound and may be prepared according to Belg. Pat. 647,043; U.S. Pat. 3,3577,986 and Villani et al., J. Med. Chem. 15, 750 (1972).
- the topical nasal steroids for use herein are corticosteroids which inhibit the release of mediators for the symptoms associated with allergic rhinitis from mast cells and basophils. They also reduce inflammation and suppress neutrophil chemotaxis.
- the topical nasal steroids herein have relatively few side effects but are known to cause nasal irritation, drying and epistaxis with use of nasal sprays.
- persons skilled in the art understand that only a sufficient amount of nasal steroid should be administered to inhibit mast cell mediator release and inflammation and no more. This amount will vary depending on whether beclomethasone, flunisolide, triamcinolone, dexamethasone or budesonide is employed.
- the nasal steroids are relatively long acting and alone can be administered once or twice daily.
- the amount of nas? 1 steroid when used in conjunction with an active ingredient requiring more frequent administration, the amount of nas? 1 steroid must be adjusted accordingly.
- beclomethasone from about 10 to about 100 meg, and preferably from about 15 to about 85 meg should be administered in this combination every 4 to 12 hours.
- the beclomethasone should constitute of the nasal spray or nasal drops composition from about 0.05 to about 0.5 mg/ml, and preferably from about 0.1 to about 0.3 mg/ml.
- flunisolide from about 30 to about 300 meg, and preferably from about 50 to about 200 meg should be administered in this combination every 4 to 12 hours.
- the flunisolide should constitute of the nasal spray or nasal drops composition from about 0.1 to about 1.0 mg/ml, and preferably from about 0.15 to about 0.5 mg/ml.
- the triamcinolone from about 10 to about 100 meg, and preferably from about 15 to about 85 meg should be administered in this combination every 4 to 12 hours.
- the triamcinolone should constitute of the nasal spray or nasal drops composition from about 0.05 to about 0.5 mg/ml, and preferably from about 0.1 to about 0.3 mg/ml.
- dexamethasone from about 40 to about 400 meg, and preferably from about 60 to about 340 meg should be administered in this combination every 4 to 12 hours.
- the dexamethasone should constitute of the nasal spray or nasal drops composition from about 0.2 to about 2.0 mg/ml, and preferably from about 0.4 to about 1.2 mg/ml.
- the budesonide from about 40 to about 400 meg, and preferably from about 60 to about 340 meg should be administered in this combination every 4 to 12 hours.
- the budesonide should constitute of the nasal spray or nasal drops composition from about 0.2 to about 2.0 mg/ml, and preferably from about 0.4 to about 1.2 mg/ml.
- the corticosteroid topical nasal steroids are, as a general matter, poorly soluble in water.
- the particles are administered in particulate form, as a micronized suspension in a suitable carrier/solvent system.
- a suitable carrier/solvent system for the treatment of the lung, it is desirable to produce aerosol particle sizes of less than 3 microns.
- the necessity of producing an aerosol of small particles is removed.
- the particle size of the corticosteroid in suspension is not critical so long as the particle is small enough that the amount of compound available for therapeutic activity is not surface area limited and the particle is stable in suspension.
- the suspension may be maintained with suitable liposomes.
- solubilizing agents include 1 ,2-propane diol, 1 ,3-propane diol, polyethylene glycol having a molecular weight of 100 to 800, dipropylene glycol, or ethanol.
- a suitable surfactant may be a pharmaceutically acceptable non-ionic, anionic or cationic surfactant.
- non-ionic surfactants include glycerol fatty acid esters such as glycerol monostearate, glycol fatty acid esters such as propylene glycol monostearate, polyhydric alcohol fatty acid esters such as polyethylene glycol (400) monooleate, polyoxyethylene fatty acid esters such as polyoxyethylene (40) stearate, polyoxyethylene fatty alcohol ethers such as polyoxyethylene (20) stearyl ether, polyoxyethylene sorbitan fatty acid esters such as polyoxyethylene sorbitan monostearate or polysorbate 20, fatty acid ethanolamides and their derivatives such as the diethanoiamide of stearic acid, and the like.
- glycerol fatty acid esters such as glycerol monostearate
- glycol fatty acid esters such as propylene glycol monostearate
- polyhydric alcohol fatty acid esters such as polyethylene glycol (400) monooleate
- polyoxyethylene fatty acid esters such
- Suitable anionic surfactants are soaps including alkali soaps, such as sodium, potassium and ammonium salts of aliphatic carboxylic acids, usually a fatty acids, such as sodium stearate.
- Organic amine soaps also included, include organic amine salts of aliphatic carboxylic acids, usually fatty acids, such as triethanolamine stearate.
- Another class of suitable soaps is the metallic soaps, salts of polyvalent metals and aliphatic carboxylic acids, usually fatty acids, such as aluminum stearate.
- suitable cationic surfactants include amine salts such as octadecyl ammonium chloride, quartemary ammonium compounds such as benzalkonium chloride.
- solubilizing agent and surfactant should be employed to stabilize the suspension/emulsion. Generally there should be employed from about 5 to about 30% w/v and preferably from 10 to about 25% w v of cosolvent. Likewise, there should be employed from about 0.1 to about 10% w/v and preferably from about 0.5 to about 5% w v of surfactant.
- Beclamethasone as used herein includes beclamethasone, beclamethasone acetate, beclamethasone valerate, beclamethasone propionate, beclamethasone dipropionate and the like, including the hydrates thereof.
- Beclamethose, 9-chloro-11 ,17,21-trihydroxy-16-methylpregna-1,4- diene-3,20-dione, may be obtained commercially and is prepared according to Brit. Pat. 912,378 and Brit. Pat. 901 ,093. Beclamethasone is commercially available.
- Flunisolide as used herein includes flunisolide and flunisolide acetate and hydrates thereof.
- Flunisolide, 6-fluoro-11 ,21-dihydroxy-16,17-[(1- methylethylidene)bis(oxy)]pregna-1 ,4-diene-3,20-dione, may be prepared using S. roseoc romogenes as in Brit. Pat. 933,867 and Chem. Abst. 60, 3070f (1964) or using Cunninghamella blakesleeana as in U.S. pat. 3,124,571. Flunisolide is also prepared in 4,273,710. Flunisolide is commercially available.
- Triamcinolone as used herein includes triamcinolone and its 16- ⁇ , 21- diacetate; triamcinolone acetonide, and its 21 -acetate, 21 -disodium phosphate, and 21 -hemisuccinate; triamcinolone benetonide and triamcinolone hexacetonide, including hydrates thereof.
- Triamcinolene, 9- fluoro-11,16,17,21 -tetrahydroxypregna-1 ,4-diene-3,20-dione may be prepared according to Bernstein et al., J. Am. Chem. Soc. 78, 5693 (1956) and 81, 1689 (1959); Thoma et al., J. Am. Chem.
- Triamcinolone acetonide may be prepared by stirring a suspension of triamcinolone in acetone in the presence of a trace of perchloric acid.
- Triamcinolone benetonide may be prepared according to Ger. Pat. 2,047,218 or U.S. Pat. 3,749,712.
- Triamcinolone hexacetonide may be prepared according to U.S. pat. 3,457,348.
- the triamcinolone and derivatives as taught herein have been sold or are available commercially.
- Dexamethasone as used herein includes dexamethasone and its 21 - phosphate, 21 -acetate, 21 -phosphate disodium salt, 21- dimethylaminoacetate, 21-isonicotinate, 17,21-dipropionate and 21 -palmitate.
- Dexamethasone, (11 ⁇ , 16 ⁇ )-9-f luoro- 11 ,17,21-trihydroxy-16-methylpregna- 1 ,4-diene-3,20-dione may be prepared according to Arth et al., J. Am. Chem. Soc. 80, 3161 (1958); Oliveto et al., J. Am. Ohem. Soc. 80, 4431 (1958); U.S. Pat. 3,007,923; Ger. Pat. 1 ,113,690 or Brit. Pat. 869,511. Dexamethasone is commercially available.
- Budesonide as used herein includes budesonide and its pharmaceutically acceptable salts.
- Preferred salts of budesonide include its palmitate, laurate, myristate, stearate, oleate, valerate and acetate salts.
- Budesonide 16,17-butylidenebis(oxy)-11 ,21-dihydroxypregna-1 ,4-diene-3,20- dione, is a well known compound and may be prepared according to U.S. Pat.
- the nasal spray or nasal drop formulation herein can contain, in addition to the compounds discussed above antimicrobial agents, antioxidants, agents to increase viscosity, isotonic agents, buffers, solubilizing agents, surface active agents and the like.
- Suitable antimicrobial agents include chlorobutanol, phenylmercuric nitrate, phenyl ethyl alcohol, thimerosal, the quaternary ammonium germicides, such as, benzalkonium chloride, benzethonium chloride or cetylpyridium chloride.
- Suitable antioxidants include sodium sulfite, sodium ascorbate, oxime sulfate, etc.
- the preferred isotonic agent is sodium chloride however, other isotonic agents such as dextrose, boric acid and sodium tartrate may be employed.
- the object of the buffer is to adjust the pH to one compatible with nasal mucous membranes and to stabilize the active ingredient. Ideally the target pH should vary between about 4 and about 6.5. Suitable buffers included phthalate buffers, borate buffers, phosphate buffers, such as HP ⁇ 4 2 7H2PO-r> acetate buffers, such as acetic acid/sodium acetate, a bicarbonate buffer such as CO2/HCO3, or a citrate buffer, such as citric acid/citrate, also it may be adjusted by simply adding an acid such as HCI to achieve the desired acidity.
- Suitable agents to increase viscosity include polyvinyl alcohol, cellulose derivatives, polyvinylpyrollidone, polysorbates or glycerine.
- Suitable surface active agents improve abso ⁇ tion by the nasal mucosa and include polyoxyl 40 stearate, polyoxyethylene 50 stearate, polysorbate 80 and octoxynol.
- concentration of the additives will be in the range as follows:
- the buffer should be added in sufficient amount to achieve the pH range stated above of about 4.0 to about 6.5.
- Aerosol formulations and nose drops are prepared as per known techniques.
- the water employed should be of an appropriate pharmacutical grade of purified water. These formulations should be administered by drop or spray every 4 to 6 hours to obtain the desired relief.
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU63924/96A AU6392496A (en) | 1995-06-29 | 1996-06-25 | The combination of topical nasal antihistamines and topical nasal steroids |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US49681495A | 1995-06-29 | 1995-06-29 | |
US08/496,814 | 1995-06-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997001337A1 true WO1997001337A1 (en) | 1997-01-16 |
Family
ID=23974249
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1996/010789 WO1997001337A1 (en) | 1995-06-29 | 1996-06-25 | The combination of topical nasal antihistamines and topical nasal steroids |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU6392496A (en) |
WO (1) | WO1997001337A1 (en) |
Cited By (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997046243A1 (en) * | 1996-06-04 | 1997-12-11 | The Procter & Gamble Company | A nasal spray containing an intranasal steroid and an antihistamine |
WO1998048839A1 (en) * | 1997-04-30 | 1998-11-05 | Warner-Lambert Company | Topical nasal antiinflammatory compositions |
WO2001022955A2 (en) * | 1999-09-30 | 2001-04-05 | Viatris Gmbh & Co. Kg | Novel combination of loteprednol and antihistamines |
US6291445B1 (en) | 1996-12-05 | 2001-09-18 | Astra Aktiebolag | Low dose budesonide formulations and uses thereof |
WO2003049770A1 (en) * | 2001-12-05 | 2003-06-19 | Alcon, Inc. | Use of an h1 antagonist and a safe steroid to treat rhinitis |
GB2389530A (en) * | 2002-06-14 | 2003-12-17 | Cipla Ltd | Pharmaceutical composition comprising azelastine and steroid |
US6686346B2 (en) | 1996-12-05 | 2004-02-03 | Astra Aktiebolag | Formulation |
US6712803B1 (en) * | 1999-08-11 | 2004-03-30 | Howard Paritsky | Drug dispensing system |
WO2004043470A1 (en) * | 2002-11-12 | 2004-05-27 | Alcon, Inc. | The use of an anti-allergy agent and a steroid to treat allergic rhinitis |
US6767901B1 (en) | 1999-10-20 | 2004-07-27 | Altana Pharma Ag | Ciclesonide contained pharmaceutical composition for application to mucosa |
WO2005030331A1 (en) * | 2003-09-26 | 2005-04-07 | Fairfield Clinical Trials, Llc | Combination antihistamine medication |
WO2005037245A2 (en) * | 2003-10-21 | 2005-04-28 | Direct-Haler A/S | A multiple route medication for the treatment of rhinitis and asthma |
US6939559B1 (en) | 1998-04-21 | 2005-09-06 | Teijin Limited | Pharmaceutical composition for application to mucosa |
JP2005539044A (en) * | 2002-08-30 | 2005-12-22 | アルタナ ファルマ アクチエンゲゼルシャフト | Use of a combination of ciclesonide and antihistamine to treat allergic rhinitis |
WO2006102494A2 (en) * | 2005-03-23 | 2006-09-28 | Elan Pharma International Limited | Nanoparticulate corticosteroid and antihistamine formulations |
EP1788816A2 (en) | 1997-11-05 | 2007-05-23 | Sony Corporation | Transform domain interpolation for resolution conversion of coded video data |
WO2009067317A2 (en) * | 2007-11-19 | 2009-05-28 | Bausch & Lomb Incorporated | Use of levocabastine for modulating generation of pro- inflammatory cytokines |
US20110038806A1 (en) * | 2003-07-29 | 2011-02-17 | Boehringer Ingelheim International Gmbh | Medicaments for inhalation comprising an anticholinergic and a steroid |
WO2011141929A2 (en) | 2010-05-11 | 2011-11-17 | Cadila Healthcare Limited | Aqueous pharmaceutical compositions of fluticasone and olopatadine |
WO2012074231A2 (en) | 2010-11-29 | 2012-06-07 | 한림제약(주) | Pharmaceutical composition including mometasone furoate and azelastine hydrochloride for nasal administration |
US8383611B1 (en) | 1999-10-20 | 2013-02-26 | Nycomed Gmbh | Ciclesonide containing aqueous pharmaceutical composition |
US9333195B2 (en) | 1999-07-14 | 2016-05-10 | Almirall, S.A. | Quinuclidine derivatives and medicinal compositions containing the same |
US9737520B2 (en) | 2011-04-15 | 2017-08-22 | Almirall, S.A. | Aclidinium for use in improving the quality of sleep in respiratory patients |
CN107737105A (en) * | 2017-11-28 | 2018-02-27 | 贵州云峰药业有限公司 | A kind of nasal cavity agent of azelastine hydrochloride composition spray and production technology |
US9919050B2 (en) | 2004-11-24 | 2018-03-20 | Meda Pharmaceuticals Inc. | Compositions comprising azelastine |
US9980959B2 (en) | 2004-05-11 | 2018-05-29 | Biolipox Ab | Method and composition for treating rhinitis |
US10064817B2 (en) | 2004-11-24 | 2018-09-04 | Meda Pharmaceuticals Inc. | Compositions comprising azelastine and methods of use thereof |
US10085974B2 (en) | 2008-03-13 | 2018-10-02 | Almirall, S.A. | Dosage and formulation |
-
1996
- 1996-06-25 WO PCT/US1996/010789 patent/WO1997001337A1/en active Application Filing
- 1996-06-25 AU AU63924/96A patent/AU6392496A/en not_active Abandoned
Non-Patent Citations (8)
Title |
---|
BUSSE W.: "NEW DIRECTIONS AND DIMENSIONS IN THE TREATMENT OF ALLERGIC RHINITIS", J.ALLERGY CLIN. IMMUNOL., vol. 82, no. 5, November 1988 (1988-11-01), pages 890 - 900, XP000603998 * |
DELAFUENTE J.C., ET AL.: "PHARMACOTHERAPY OF ALLERGIC RHINITIS", CLINICAL PHARMACY, vol. 8, no. 7, July 1989 (1989-07-01), pages 474 - 485, XP000603999 * |
HOLLINGSWORTH: "ALLERGIC RHINOCONJUCTIVITIS: CURRENT THERAPY", HOSPITAL PRACTICE, vol. 31, no. 6, 15 June 1996 (1996-06-15), pages 61 - 73, XP000604174 * |
HORAK F.: "SEASONAL ALLERGIC RHINITIS", DRUGS, vol. 45, no. 4, 1993, pages 518 - 527, XP000603981 * |
LUND V.: "PRACTICAL APPLICATION OF THE INTERNATIONAL CONSENSUS ON THE MANAGEMENT OF RHINITIS", CLINICAL IMMUNOTHERAPEUTICS, vol. 4, no. 4, April 1995 (1995-04-01), pages 270 - 278, XP000604030 * |
MEETING OF THE ROYAL BELGIAN SOCIETY FOR ENT, HEAD AND NECK SURGERY, February 1995 (1995-02-01), BRUSSELS * |
PURELLO D'AMBROSIO F., ET AL.: "LEVOCABASTINA VERSUS FLUNISOLIDE NEL TRATTAMENTO DELLA RINITE ALLERGICA PERENNE", INTERNISTA, vol. 3, September 1995 (1995-09-01), pages 167 - 170, XP000604083 * |
WANG D., ET AL.: "THE ACTIVITY OF RECENT ANTI-ALLERGIC DRUGS IN THE TREATMENT OF SEASONAL ALLERGIC RHINITIS", ACTA OTORHINOLARYNGOL., vol. 50, no. 1, January 1996 (1996-01-01), pages 25 - 32, XP000604028 * |
Cited By (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997046243A1 (en) * | 1996-06-04 | 1997-12-11 | The Procter & Gamble Company | A nasal spray containing an intranasal steroid and an antihistamine |
US6986904B2 (en) | 1996-12-05 | 2006-01-17 | Astrazeneca Ab | Formulation |
US6686346B2 (en) | 1996-12-05 | 2004-02-03 | Astra Aktiebolag | Formulation |
US6291445B1 (en) | 1996-12-05 | 2001-09-18 | Astra Aktiebolag | Low dose budesonide formulations and uses thereof |
WO1998048839A1 (en) * | 1997-04-30 | 1998-11-05 | Warner-Lambert Company | Topical nasal antiinflammatory compositions |
EP1788816A2 (en) | 1997-11-05 | 2007-05-23 | Sony Corporation | Transform domain interpolation for resolution conversion of coded video data |
BG64919B1 (en) * | 1998-04-21 | 2006-09-29 | Teijin Ltd. | Pharmaceutical composition for mucous membrane application |
US7235247B2 (en) | 1998-04-21 | 2007-06-26 | Teijin Pharma Limited | Pharmaceutical composition for application to mucosa |
US6939559B1 (en) | 1998-04-21 | 2005-09-06 | Teijin Limited | Pharmaceutical composition for application to mucosa |
US9333195B2 (en) | 1999-07-14 | 2016-05-10 | Almirall, S.A. | Quinuclidine derivatives and medicinal compositions containing the same |
USRE46417E1 (en) | 1999-07-14 | 2017-05-30 | Almirall, S.A. | Quinuclidine derivatives and their use as muscarinic M3 receptor ligands |
US9687478B2 (en) | 1999-07-14 | 2017-06-27 | Almirall, S.A. | Quinuclidine derivatives and medicinal compositions containing the same |
US10588895B2 (en) | 1999-07-14 | 2020-03-17 | Almirall, S.A. | Quinuclidine derivatives and medicinal compositions containing the same |
US10034867B2 (en) | 1999-07-14 | 2018-07-31 | Almirall, S.A. | Quinuclidine derivatives and medicinal compositions containing the same |
US6712803B1 (en) * | 1999-08-11 | 2004-03-30 | Howard Paritsky | Drug dispensing system |
US7022687B1 (en) | 1999-09-30 | 2006-04-04 | Asta Medica Ag | Combination of loteprednol and antihistamines |
WO2001022955A3 (en) * | 1999-09-30 | 2001-05-17 | Asta Medica Ag | Novel combination of loteprednol and antihistamines |
JP2012001558A (en) * | 1999-09-30 | 2012-01-05 | Meda Pharma Gmbh & Co Kg | Novel combination of loteprednol and antihistamine |
WO2001022955A2 (en) * | 1999-09-30 | 2001-04-05 | Viatris Gmbh & Co. Kg | Novel combination of loteprednol and antihistamines |
JP2003510275A (en) * | 1999-09-30 | 2003-03-18 | フィアトリス ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | Novel combination of loteprednol and antihistamine |
US6767901B1 (en) | 1999-10-20 | 2004-07-27 | Altana Pharma Ag | Ciclesonide contained pharmaceutical composition for application to mucosa |
US8383611B1 (en) | 1999-10-20 | 2013-02-26 | Nycomed Gmbh | Ciclesonide containing aqueous pharmaceutical composition |
WO2003049770A1 (en) * | 2001-12-05 | 2003-06-19 | Alcon, Inc. | Use of an h1 antagonist and a safe steroid to treat rhinitis |
US8937057B2 (en) | 2002-06-14 | 2015-01-20 | Cipla Limited | Combination of azelastine and mometasone for nasal administration |
AU2009243422C1 (en) * | 2002-06-14 | 2014-01-09 | Cipla Limited | Combination of azelastine and steroids |
EP2075000B1 (en) | 2002-06-14 | 2015-07-22 | Cipla Limited | Combination of azelastine and ciclesonide |
GB2389530B (en) * | 2002-06-14 | 2007-01-10 | Cipla Ltd | Pharmaceutical compositions |
AU2009243422B2 (en) * | 2002-06-14 | 2012-03-29 | Cipla Limited | Combination of azelastine and steroids |
US9901585B2 (en) | 2002-06-14 | 2018-02-27 | Cipla Limited | Combination of azelastine and fluticasone for nasal administration |
US8933060B2 (en) | 2002-06-14 | 2015-01-13 | Cipla Limited | Combination of azelastine and ciclesonide for nasal administration |
EP2072051A1 (en) * | 2002-06-14 | 2009-06-24 | Cipla Ltd. | Combination of azelastine and mometasone |
EP2075000A1 (en) * | 2002-06-14 | 2009-07-01 | Cipla Ltd. | Combination of azelastine and ciclesonide |
US9259428B2 (en) | 2002-06-14 | 2016-02-16 | Cipla Limited | Combination of azelastine and fluticasone for nasal administration |
AU2003244799B2 (en) * | 2002-06-14 | 2009-09-10 | Cipla Limited | Combination of azelastine and steroids |
KR101301558B1 (en) * | 2002-06-14 | 2013-09-04 | 씨아이피엘에이 엘티디. | Combination of azelastine and steroids |
KR101301061B1 (en) * | 2002-06-14 | 2013-08-28 | 씨아이피엘에이 엘티디. | Combination of azelastine and steroids |
GB2389530A (en) * | 2002-06-14 | 2003-12-17 | Cipla Ltd | Pharmaceutical composition comprising azelastine and steroid |
US8318709B2 (en) | 2002-06-14 | 2012-11-27 | Cipla Limited | Combination of azelastine and mometasone for nasal administration |
US8304405B2 (en) | 2002-06-14 | 2012-11-06 | Cipla Limited | Combination of azelastine and ciclesonide for nasal administration |
AU2009243420B2 (en) * | 2002-06-14 | 2012-10-11 | Cipla Limited | Combination of azelastine and steroids |
US8163723B2 (en) | 2002-06-14 | 2012-04-24 | Cipla Limited | Combination of azelastine and steroids |
WO2003105856A1 (en) * | 2002-06-14 | 2003-12-24 | Cipla Limited | Combination of azelastine and steroids |
KR101119895B1 (en) * | 2002-06-14 | 2012-02-22 | 씨아이피엘에이 엘티디. | Combination of azelastine and steroids |
JP2005539044A (en) * | 2002-08-30 | 2005-12-22 | アルタナ ファルマ アクチエンゲゼルシャフト | Use of a combination of ciclesonide and antihistamine to treat allergic rhinitis |
US8486923B2 (en) | 2002-08-30 | 2013-07-16 | Takeda Gmbh | Use of the combination of ciclesonide and antihistamines for the treatment of allergic rhinitis |
US7879832B2 (en) | 2002-08-30 | 2011-02-01 | Nycomed Gmbh | Use of the combination of ciclesonide and antihistamines for the treatment of allergic rhinitis |
JP2011021043A (en) * | 2002-08-30 | 2011-02-03 | Nycomed Gmbh | Use of combination of ciclesonide and antihistamine for treatment of allergic rhinitis |
JP4746318B2 (en) * | 2002-08-30 | 2011-08-10 | ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング | A pharmaceutical composition for the treatment of allergic rhinitis comprising a combination of ciclesonide and an antihistamine |
EP2295062A1 (en) | 2002-08-30 | 2011-03-16 | Nycomed GmbH | The use of the combination of ciclesonide and antihistamines for the treatment of allergic rhinitis |
CN1297275C (en) * | 2002-11-12 | 2007-01-31 | 爱尔康公司 | The use of an anti-allergy agent and a steroid to treat allergic rhinitis |
WO2004043470A1 (en) * | 2002-11-12 | 2004-05-27 | Alcon, Inc. | The use of an anti-allergy agent and a steroid to treat allergic rhinitis |
JP2006508138A (en) * | 2002-11-12 | 2006-03-09 | アルコン,インコーポレイテッド | Use of antiallergic agents and steroids to treat allergic rhinitis |
US20110038806A1 (en) * | 2003-07-29 | 2011-02-17 | Boehringer Ingelheim International Gmbh | Medicaments for inhalation comprising an anticholinergic and a steroid |
WO2005030331A1 (en) * | 2003-09-26 | 2005-04-07 | Fairfield Clinical Trials, Llc | Combination antihistamine medication |
WO2005037245A2 (en) * | 2003-10-21 | 2005-04-28 | Direct-Haler A/S | A multiple route medication for the treatment of rhinitis and asthma |
WO2005037245A3 (en) * | 2003-10-21 | 2005-08-11 | Direct Haler As | A multiple route medication for the treatment of rhinitis and asthma |
US9980959B2 (en) | 2004-05-11 | 2018-05-29 | Biolipox Ab | Method and composition for treating rhinitis |
US9919050B2 (en) | 2004-11-24 | 2018-03-20 | Meda Pharmaceuticals Inc. | Compositions comprising azelastine |
US10064817B2 (en) | 2004-11-24 | 2018-09-04 | Meda Pharmaceuticals Inc. | Compositions comprising azelastine and methods of use thereof |
US8003127B2 (en) | 2005-03-23 | 2011-08-23 | Elan Pharma International Limited | Nanoparticulate corticosteroid and antihistamine formulations methods of making, and methods of administering thereof |
WO2006102494A2 (en) * | 2005-03-23 | 2006-09-28 | Elan Pharma International Limited | Nanoparticulate corticosteroid and antihistamine formulations |
JP2008534509A (en) * | 2005-03-23 | 2008-08-28 | エラン ファーマ インターナショナル リミテッド | Nanoparticulate corticosteroid and antihistamine preparations |
WO2006102494A3 (en) * | 2005-03-23 | 2007-01-25 | Elan Pharma Int Ltd | Nanoparticulate corticosteroid and antihistamine formulations |
WO2009067317A2 (en) * | 2007-11-19 | 2009-05-28 | Bausch & Lomb Incorporated | Use of levocabastine for modulating generation of pro- inflammatory cytokines |
WO2009067317A3 (en) * | 2007-11-19 | 2009-08-06 | Bausch & Lomb | Use of levocabastine for modulating generation of pro- inflammatory cytokines |
US10085974B2 (en) | 2008-03-13 | 2018-10-02 | Almirall, S.A. | Dosage and formulation |
US11000517B2 (en) | 2008-03-13 | 2021-05-11 | Almirall, S.A. | Dosage and formulation |
WO2011141929A2 (en) | 2010-05-11 | 2011-11-17 | Cadila Healthcare Limited | Aqueous pharmaceutical compositions of fluticasone and olopatadine |
US8859531B2 (en) | 2010-11-29 | 2014-10-14 | Hanlim Pharmaceutical Co., Ltd | Pharmaceutical composition including mometasone furoate and azelastine hydrochloride for nasal administration |
WO2012074231A2 (en) | 2010-11-29 | 2012-06-07 | 한림제약(주) | Pharmaceutical composition including mometasone furoate and azelastine hydrochloride for nasal administration |
US9737520B2 (en) | 2011-04-15 | 2017-08-22 | Almirall, S.A. | Aclidinium for use in improving the quality of sleep in respiratory patients |
CN107737105A (en) * | 2017-11-28 | 2018-02-27 | 贵州云峰药业有限公司 | A kind of nasal cavity agent of azelastine hydrochloride composition spray and production technology |
Also Published As
Publication number | Publication date |
---|---|
AU6392496A (en) | 1997-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1997001337A1 (en) | The combination of topical nasal antihistamines and topical nasal steroids | |
US8486923B2 (en) | Use of the combination of ciclesonide and antihistamines for the treatment of allergic rhinitis | |
US7691811B2 (en) | Transporter-enhanced corticosteroid activity and methods and compositions for treating dry eye | |
US20110086023A1 (en) | Combination antihistamine medication | |
US20040097474A1 (en) | Use of an anti-allergy agent and a steroid to treat nasal conditions | |
US20060228306A1 (en) | Combination antihistamine and steroid medication | |
EP0780127A1 (en) | A nasal spray containing a steroid and a antihistamine | |
US4945089A (en) | Use of tetrahydrocortexolone to prevent elevations in intraocular pressure caused by corticosteroids | |
US20090022671A1 (en) | Treatment methods | |
WO1997001341A1 (en) | The combination of topical nasal mast cell stabilizers and topical nasal steroids | |
JP5278313B2 (en) | Transporter-enhanced corticosteroid activity | |
Schenkel | Features of mometasone furoate nasal spray and its utility in the management of allergic rhinitis | |
Tse et al. | Corticosteroid aerosols in the treatment of asthma | |
Al-Mohaimeid | A parallel-group comparison of budesonide and beclomethasone dipropionate for the treatment of perennial allergic rhinitis in adults | |
WO1997001340A1 (en) | The combination of topical nasal antihistamines and topical nasal mast cell stabilizers | |
Martin | Pharmacology of nasal medications: an update | |
CA2241879A1 (en) | Use of inhibitors of phosphodiesterase 4 for treating allergic rhinitis | |
Steyn | Triamcinolone acetonide aqueous... | |
Kaulbach et al. | 64 Effects of nedocrumil sodium on allergen-induced rhinitis in humans | |
Drouin et al. | 63 Multicentre clinical evaluation of the efficacy and safety of noberastine, a new H1-antagonist, in seasonal allergic rhinitis | |
NZ616149A (en) | Nasal pharmaceutical formulation comprising fluticasone | |
MXPA06008935A (en) | Treatment of rhinitis with anticholinergics alone in combination with antihistamines phosphodiesterase 4 inhibitors, or corticosteroids |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |